Where the Value Is: Undervalued Dividend Stocks for Spring 2026

The broad market is expensive. The S&P 500 is trading above 31x earnings — historically elevated territory that makes finding genuine value harder than it's been in years. But pockets of deep undervaluation persist, and right now some of the most compelling opportunities sit at the intersection of low valuations, strong free cash flow, and growing dividends.

So where's the value? Here's what's standing out this week.

HEALTHCARE DEVICES & MANAGED CARE

This sector is generating the most conviction among value-oriented analysts. Medtronic (MDT) is trading 18% below Morningstar's $112 fair value estimate. It's the largest pure-play medical device maker in the world, returns 60–70% of free cash flow to shareholders annually, and has earned Dividend Aristocrat status. Despite the discount, it earns a wide economic moat rating — durable competitive advantages that should compound returns for patient investors.

UnitedHealth Group (UNH) is another name worth watching. It trades 34% below a $427 fair value estimate after near-term earnings uncertainty created a rare opening. The company pays out roughly 30% of profits as dividends, leaving significant room for continued growth. Becton Dickinson (BDX) rounds out the healthcare value story — a Dividend King trading at a forward P/E of around 14, compared to a sector average closer to 27.

ENERGY: INCOME WITH A MARGIN OF SAFETY

Midstream and upstream energy names are offering a rare combination of high yields and low valuations. Enterprise Products Partners (EPD) stands out: a 7% yield, 27 consecutive years of distribution increases, and a valuation of just 7.7x forward cash flow. The company returned $61 billion to shareholders since its IPO and is projecting double-digit cash flow growth in 2026.

For those preferring traditional oil and gas, Devon Energy (DVN) and EOG Resources (EOG) both screen well. EOG returns over 70% of free cash flow to shareholders through dividends and buybacks, has been growing its dividend since 1999, and maintains a strong balance sheet. DVN trades roughly 30% below Morningstar's fair value estimate.

CONSUMER STAPLES: CONTRARIAN OPPORTUNITY

Consumer staples have been out of favor, and that's created some unusually wide discounts. Kraft Heinz (KHC) trades more than 50% below Morningstar's fair value — a number that reflects a company going through a structural split that the market appears to be heavily penalizing. Kimberly-Clark (KMB) and Mondelez International (MDLZ) are two steadier names, each carrying 5-star Morningstar ratings and trading 20–25% below estimated fair value with solid dividend growth profiles.

REITS: YIELD WITHOUT OVERPAYING

Healthpeak Properties (DOC) — a REIT focused on medical offices and life science facilities — is trading roughly 40% below fair value with a 7%+ dividend yield. Netstreit Corp (NTST), a net-lease REIT, screens at 13.96x forward earnings against a sector average of 18.35x, and carries a 4.66% yield with a Strong Buy consensus from 24 analysts. Realty Income (O) has now paid 669 consecutive monthly dividends — not cheap, but a cornerstone income holding for good reason.

THE BROADER PICTURE

Dividend per share growth for S&P 500 companies rose 4% in 2025 and is expected to grow another 5% this year. That's a meaningful tailwind for income investors, and it's happening precisely when equity valuations in the broad market look stretched. The companies above aren't exciting — they make insulin pumps, diapers, natural gas pipelines, and ketchup. But they generate real cash, return it consistently to shareholders, and today you can buy most of them at prices that leave meaningful room for error.

That's the kind of setup value investors wait for.